开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Nadiyeh Rouhi
The use of biomarkers in basic and clinical analysis further as in clinical observe has become thus commonplace that their presence as primary endpoints in clinical trials is currently accepted nearly while not question. Within the case of specific biomarkers that are well characterized and repeatedly shown to properly predict relevant clinical outcomes across a range of treatments and populations, this use is entirely even and applicable. In several cases, however, the “validity” of biomarkers is assumed wherever, in fact, it ought to still be evaluated and reevaluated. This text can take into account the present abstract standing of biomarkers as clinical and diagnostic tools and as surrogate endpoints in clinical analysis with the goal of providing context for decoding studies that trust heavily on such biological measures.